Vera Therapeutics (VERA) has provided an announcement.
Vera Therapeutics, Inc. has enhanced its board by appointing Christy Oliger as a Class III Director, effective immediately, with her term set to expire at the 2027 Annual Meeting of Stockholders. Alongside her directorship, she will join the Nominating and Corporate Governance Committee and receive a stock option award for 25,000 shares, vesting over three years, and a prorated annual cash retainer. Additionally, she will be eligible for future annual option grants and has been awarded fully vested restricted stock units for prior consulting services. Her compensation and stock options are governed by the company’s established policies, and she’s secured an indemnification agreement with the company.
Find detailed analytics on VERA stock on TipRanks’ Stock Analysis page.
